Sickle Cell Disease is one of the most common genetic disorders in the United States and is incredibly prevalent
throughout Africa and the Middle East. By 2050, the annual number of newborns with Sickle Cell Disease is projected to
increase by 33%. A similar story can be told about Beta-Thalassemia: another hemoglobinopathy that has no standard
treatment. The future of treating hemoglobinopathies looks bleak and more research must be done to prevent fatalities and the
lifelong problems associated with it now.